Biosyent Financials

RX Stock  CAD 11.20  0.40  3.70%   
You can use Biosyent fundamental data analysis to find out if markets are presently mispricing the company. We were able to interpolate thirty-three available fundamental indicators for Biosyent, which can be compared to its peers. The stock experiences an unexpected upward trend. Watch out for market signals. Check odds of Biosyent to be traded at C$13.44 in 90 days. Key indicators impacting Biosyent's financial strength include:
Current ValueLast YearChange From Last Year 10 Year Trend
Debt Equity Ratio0.03840.0404
Notably Down
Slightly volatile
Current Ratio3.915.83
Way Down
Slightly volatile
  
Please note, the imprecision that can be found in Biosyent's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Biosyent. Check Biosyent's Beneish M Score to see the likelihood of Biosyent's management manipulating its earnings.

Biosyent Stock Summary

Biosyent competes with Cipher Pharmaceuticals, Covalon Technologies, and Knight Therapeutics. BioSyent Inc., a specialty pharmaceutical company, sources, acquires or in-licenses, develops, and sells various pharmaceutical and other healthcare products in Canada and internationally. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006 to reflect its forward focus on the pharmaceutical market. BIOSYENT INC operates under Drug Manufacturers - Specialty Generic classification in Canada and is traded on TSX Venture Exchange.
Foreign Associate
  USA
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
InstrumentCanada Stock View All
ExchangeTSX Venture Exchange
ISINCA0906901081
Business Address2476 Argentia Road,
SectorPharmaceuticals
IndustryHealth Care
BenchmarkDow Jones Industrial
Websitewww.biosyent.com
Phone905 206 0013
CurrencyCAD - Canadian Dollar
You should never invest in Biosyent without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Biosyent Stock, because this is throwing your money away. Analyzing the key information contained in Biosyent's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.

Biosyent Key Financial Ratios

There are many critical financial ratios that Biosyent's investors are exposed to on a daily basis, but they are usually grouped into few meaningful categories from each financial statement that Biosyent reports annually and quarterly.

Biosyent Key Balance Sheet Accounts

202020212022202320242025 (projected)
Total Assets33.6M37.2M40.5M41.5M47.8M50.1M
Other Current Liab328.8K98.7K318.0K138.4K124.6K228.7K
Net Debt(18.6M)(16.5M)(6.5M)(3.7M)(3.3M)(3.5M)
Retained Earnings19.1M24.1M25.9M27.5M31.7M33.2M
Accounts Payable3.7M3.6M5.1M5.1M5.8M6.1M
Cash20.3M18.0M7.9M4.9M5.6M5.4M
Inventory2.1M2.2M4.5M5.9M6.8M7.1M
Other Current Assets307.6K456.0K255.0K243.5K280.0K163.3K
Total Liab6.8M5.6M7.1M6.8M7.8M8.2M
Total Current Assets29.8M34.1M37.1M35.9M41.3M43.3M
Short Term Debt151.9K161.8K174.1K183.3K165.0K171.5K
Intangible Assets1.0M874.0K1.2M1.2M1.3M1.4M
Net Receivables1.8M3.2M3.7M3.5M4.1M4.3M
Common Stock6.4M5.8M5.4M5.1M4.6M5.4M
Other Liab102.9K79.7K80.2K182.4K209.7K153.4K
Net Tangible Assets24.7M25.8M30.7M32.3M37.1M21.9M
Other Assets758.8K406.5K639.1K1.01.151.09
Net Invested Capital26.8M31.6M33.4M34.8M40.0M31.8M
Net Working Capital24.6M29.9M31.4M30.3M34.9M29.1M
Capital Stock6.4M5.8M5.4M5.1M4.6M5.0M

Biosyent Key Income Statement Accounts

202020212022202320242025 (projected)
Total Revenue22.3M28.6M27.9M31.6M36.3M38.1M
Gross Profit17.4M22.6M22.9M25.1M28.9M30.4M
Operating Income5.0M8.2M7.0M7.5M8.7M9.1M
Ebit5.4M8.5M7.4M7.5M8.7M9.1M
Ebitda5.9M9.0M7.9M8.0M9.2M9.6M
Cost Of Revenue4.9M6.0M5.1M6.4M7.4M7.8M
Income Before Tax5.2M8.4M7.4M8.5M9.8M10.3M
Net Income3.8M6.3M5.5M6.5M7.4M7.8M
Income Tax Expense1.4M2.1M2.0M2.1M2.4M2.5M
Interest Expense92.9K85.2K77.1K68.4K78.7K68.6K
Research Development241.6K276.5K218.5K83.3K95.8K112.1K
Tax Provision1.4M2.1M2.0M2.1M2.4M1.9M
Net Interest Income170.2K51.8K448.7K1.1M1.2M1.3M
Interest Income263.1K137.0K525.8K1.1M1.3M1.4M

Biosyent Key Cash Accounts

202020212022202320242025 (projected)
Change In Cash6.8M(2.3M)(10.2M)(392.3K)(353.1K)(335.4K)
Free Cash Flow6.7M4.6M4.4M3.2M3.6M1.9M
Depreciation510.4K457.1K451.0K455.3K523.6K549.8K
Other Non Cash Items(143.9K)(154.8K)(298.9K)(18.4K)(16.6K)(17.4K)
Capital Expenditures174.3K93.2K519.3K2.7M3.1M3.2M
Net Income3.8M6.3M5.5M6.5M7.4M7.8M
End Period Cash Flow20.3M18.0M7.9M4.9M5.6M5.4M
Change To Inventory65.6K(130.8K)(2.4M)(1.5M)(1.3M)(1.3M)
Investments3.2M(4.9M)(10.7M)883.8K795.5K835.2K
Change To Netincome681.0K94.7K111.4K131.9K118.7K112.8K
Dividends Paid7.4K10.3K484.0K1.9M2.2M2.3M

Biosyent Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Biosyent's current stock value. Our valuation model uses many indicators to compare Biosyent value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Biosyent competition to find correlations between indicators driving Biosyent's intrinsic value. More Info.
Biosyent is currently regarded as top stock in return on equity category among its peers. It also is currently regarded as top stock in return on asset category among its peers reporting about  0.60  of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Biosyent is roughly  1.66 . At this time, Biosyent's Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Biosyent's earnings, one of the primary drivers of an investment's value.

Biosyent Systematic Risk

Biosyent's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Biosyent volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Biosyent correlated with the market. If Beta is less than 0 Biosyent generally moves in the opposite direction as compared to the market. If Biosyent Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Biosyent is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Biosyent is generally in the same direction as the market. If Beta > 1 Biosyent moves generally in the same direction as, but more than the movement of the benchmark.

Biosyent Total Assets Over Time

Today, most investors in Biosyent Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Biosyent's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Biosyent growth as a starting point in their analysis.

Price Earnings To Growth Ratio

0.88

At this time, Biosyent's Price Earnings To Growth Ratio is fairly stable compared to the past year.

Biosyent March 17, 2025 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of Biosyent help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Biosyent. We use our internally-developed statistical techniques to arrive at the intrinsic value of Biosyent based on widely used predictive technical indicators. In general, we focus on analyzing Biosyent Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Biosyent's daily price indicators and compare them against related drivers.

Additional Tools for Biosyent Stock Analysis

When running Biosyent's price analysis, check to measure Biosyent's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Biosyent is operating at the current time. Most of Biosyent's value examination focuses on studying past and present price action to predict the probability of Biosyent's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Biosyent's price. Additionally, you may evaluate how the addition of Biosyent to your portfolios can decrease your overall portfolio volatility.